Clinical trials: Meningococcal Immunisation
Meningococcal Immunisation, Healthy Volunteers
Study on Immunogenicity and Safety of a Meningococcal ACYW Conjugate Vaccine in Healthy Infants and Toddlers
This study was conducted to support a 2-dose series (1+1 vaccination schedule) for immunization of individuals from 6 months of age.
- Trial name
- NCT06284915
- Testing
- MenACYW conjugate vaccine
- Where
- 45 sites in Czechia, Denmark and 4 more
- Volunteers
- 840 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Meningococcal Immunisation, Healthy Volunteers
Study on an Investigational Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Administered as a 5- and/or 10-year Booster Doses in Children and Adolescents Vaccinated 5 or 10 Years Earlier as Toddlers
The purpose of the MEQ00073 study is to describe the immunogenicity and safety of a booster dose and persistence of a priming dose of MenACYW conjugate vaccine (MenQuadfi®) in adolescents who had been vaccinated approximately 10…
- Trial name
- NCT04936685
- Testing
- Meningococcal Polysaccharide (Serogroups A, C, W, and Y) Tetanus Toxoid Conjugate Vaccine
- Where
- 27 sites in Finland, Germany and 2 more
- Volunteers
- 209 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Meningococcal Immunisation, Healthy Volunteers
Study of Immunogenicity and Safety of MenQuadfi® as a Booster Vaccine in Toddlers 12 to 23 Months, Regardless of the Quadrivalent Meningococcal Conjugate Vaccine Used for Priming in Infancy
This study evaluated the immunogenicity and safety of a single dose of MenQuadfi® administered as a booster vaccine in toddlers 12 - 23 months of age in Argentina who had been primed with at least 1 dose of the quadrivalent…
- Trial name
- NCT05929651
- Testing
- MenACYW conjugate vaccine
- Where
- 2 sites in Argentina
- Volunteers
- 71 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Meningococcal Immunisation (Healthy Volunteers)
Study on a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Compared to Two Meningococcal Reference Vaccines in European Toddlers
Primary Objective: To demonstrate: the non-inferiority of the seroprotection rate (antibody titers greater than or equal to [>=] 1:8) to meningococcal serogroup C following the administration of MenACYW Conjugate or Nimenrix® as…
- Trial name
- NCT03890367
- Testing
- Meningococcal polysaccharide (serogroups A, C, Y, and W) tetanus toxoid Conjugate vaccine, Meningococcal polysaccharide group A, C, W-135 and Y Conjugate vaccine, Meningococcal group C polysaccharide Conjugate vaccine adsorbed
- Where
- 29 sites in Denmark, Finland and 1 more
- Volunteers
- 707 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Meningococcal Immunisation (Healthy Volunteers)
Study to Evaluate the Immune Response After a Booster Dose of a Quadrivalent Meningococcal (MenACYW) Conjugate Vaccine When Administered Alone or Concomitantly With a Licensed Meningococcal Serogroup B Vaccine, in Participants Who Received Primary Quadrivalent Meningococcal Conjugate Vaccine (MCV4)
Primary Objective: To demonstrate the vaccine seroresponse sufficiency of meningococcal serogroups A, C, Y, and W following the administration of a booster dose of meningococcal Polysaccharide (Serogroups A, C, Y and W) Tetanus…
- Trial name
- NCT04084769
- Testing
- Meningococcal polysaccharide (serogroups A, C, Y, and W) tetanus toxoid Conjugate vaccine MenACYW Conjugate vaccine, Meningococcal Group B vaccine (Trumenba®), Meningococcal group B vaccine (Bexsero®)
- Where
- 30 sites in United States, Puerto Rico
- Volunteers
- 570 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Meningococcal Immunisation (Healthy Volunteers)
Study of a Quadrivalent Meningococcal Conjugate Vaccine as a Single Dose Compared With a Single Dose of a Meningococcal Reference Vaccine in Children, Adolescents, and Adults 2 to 55 Years of Age
Primary Objective: To demonstrate the non-inferiority of the antibody responses to meningococcal serogroups A, C, Y, and W following the administration of a single dose of Meningococcal Polysaccharide (Serogroups A, C, Y, and W)…
- Trial name
- NCT04368429
- Testing
- Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine (MenACYW Conjugate Vaccine), Meningococcal (Groups A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine
- Where
- 4 sites in Japan
- Volunteers
- 360 people, healthy volunteers welcome
- Sponsor
- Sanofi
Meningococcal Immunisation, Healthy Volunteers
Study on a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Compared to a Meningococcal Reference Vaccine, and When Given Alone or With Two Other Vaccines in Healthy Adolescents
Primary Objective: To demonstrate the non-inferiority of the seroprotection rate (serum bactericidal assay using human complement [hSBA] titer greater than or equal to [>=] 1:8) to meningococcal serogroups A, C, W, and Y…
- Trial name
- NCT04490018
- Testing
- Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine (MenACYW Conjugate vaccine), Meningococcal group A, C, W-135, and Y conjugate vaccine, Human Papillomavirus 9-valent Vaccine (9vHPV)
- Where
- 23 sites in Hungary, Italy and 2 more
- Volunteers
- 463 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company